Chief Executive
James Barder is the Group’s Chief Executive. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for shareholder and investor relations and leads commercial negotiations. He is also a Non-Executive Director of Caisson Investment Management and a Director of the Mary How Trust for Cancer Prevention.
Managing Director of Aon Capital Markets Limited and Non-Executive Director of Lorega Limited. James predominantly worked in the field of insurance and finance including firms he founded.
Over 25 years of experience in setting up, managing and running companies.
Executive Director and Head of R&D
Ken James is the Head of R&D. He oversees the development, regulatory and manufacturing strategies for the Group’s existing pipeline and the evaluation of early stage pipeline opportunities. He is also an Executive Director.
Senior Vice President of Research and Development for GlaxoSmithKline Worldwide Consumer Healthcare, having worked in the UK and the United States.
Over 40 years’ experience in the research, development and commercialisation of consumer healthcare products.
Finance Director, Chief Operating Officer and Company Secretary
Angela joined the Group in February 2018. She leads the Group’s finance, HR and IT functions, inputs into commercial and financial strategy, leads the Group's compliance procedures and is a principal contact for shareholder and investor relations matters.
Senior financial roles in a diverse range of industries, including 7 years as UK Finance Director at Shield Therapeutics plc.
Strategic and operational financial experience of developing and commercialising pharmaceutical products.
Non-Executive Chairman
John Clarke is the Chairman of Futura Medical plc. He chairs the Nominations Committee and is a member of the Audit Committee and the Remuneration Committee. He is also the Non-Executive Chairman of Science in Sport plc, Kind Consumer Holdings Limited and is a senior adviser to Helios Investment Partners LLP.
Retired from GSK as President of GSK Consumer Healthcare. Under his leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. Non-Executive Chairman of Quantum Pharma plc, which was subsequently acquired by Clinigen plc.
Extensive experience of the healthcare sector, having worked at a senior level at GSK for more than 35 years.
Senior Independent Non-Executive Director
Jonathan Freeman is a Senior Independent Non-Executive Director. He chairs the Audit Committee and the Remuneration Committee and is also a member of the Nominations Committee. He is also a Non-Executive Director of Kingswood Holdings Limited.
Non-Executive Director of Braveheart Investment Group plc, Director of Beeson Gregory, Chief Executive Officer of Syndicate Asset Management plc, a Director of Hume Capital Securities plc and a Director of Bould Opportunities plc.
Over 25 years of experience in the financial services sector, guidance on City regulatory matters, corporate finance and investor relations.